HK1226070B - 酪氨酸蛋白激酶抑制劑 - Google Patents

酪氨酸蛋白激酶抑制劑

Info

Publication number
HK1226070B
HK1226070B HK16114476A HK16114476A HK1226070B HK 1226070 B HK1226070 B HK 1226070B HK 16114476 A HK16114476 A HK 16114476A HK 16114476 A HK16114476 A HK 16114476A HK 1226070 B HK1226070 B HK 1226070B
Authority
HK
Hong Kong
Prior art keywords
bruton
inhibitors
tyrosine kinase
tyrosine
kinase
Prior art date
Application number
HK16114476A
Other languages
English (en)
Inventor
Romyr Dominique
Norman Kong
Yan Lou
Francisco Javier Lopeztapia
Sung-Sau So
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1226070B publication Critical patent/HK1226070B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16114476A 2013-12-13 2016-12-20 酪氨酸蛋白激酶抑制劑 HK1226070B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915588P 2013-12-13 2013-12-13

Publications (1)

Publication Number Publication Date
HK1226070B true HK1226070B (zh) 2017-09-22

Family

ID=52016583

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16114476A HK1226070B (zh) 2013-12-13 2016-12-20 酪氨酸蛋白激酶抑制劑

Country Status (12)

Country Link
US (1) US9802920B2 (zh)
EP (1) EP3080098B1 (zh)
JP (1) JP6294490B2 (zh)
KR (1) KR101822767B1 (zh)
CN (1) CN105722834B (zh)
BR (1) BR112016013541B1 (zh)
CA (1) CA2929785C (zh)
HK (1) HK1226070B (zh)
MX (1) MX2016006351A (zh)
RU (1) RU2653500C2 (zh)
TW (1) TWI540130B (zh)
WO (1) WO2015086636A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015086635A1 (en) 2013-12-13 2015-06-18 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
EP3312172B1 (en) * 2015-06-17 2020-05-06 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives useful as src kinase inhibitors
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US20030236288A1 (en) 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
EA014191B1 (ru) 2003-06-24 2010-10-29 Юнироял Кемикал Компани, Инк. Фунгицидные феноксифенилгидразиновые производные
DK2298743T3 (da) 2003-06-26 2012-11-26 Novartis Ag p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
WO2007062318A2 (en) 2005-11-18 2007-05-31 Smithkline Beecham Corporation Chemical compounds
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
IN2012DN01249A (zh) * 2009-08-07 2015-05-15 Chugai Pharmaceutical Co Ltd
MX2012003539A (es) 2009-09-24 2012-04-30 Hoffmann La Roche Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
US9840515B2 (en) 2010-12-09 2017-12-12 University of Pittsburgh—of the Commonwealth System of Higher Education Protein kinase D inhibitors
JP5620417B2 (ja) 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
MX2014005285A (es) * 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.

Also Published As

Publication number Publication date
RU2653500C2 (ru) 2018-05-10
JP6294490B2 (ja) 2018-03-14
KR20160081982A (ko) 2016-07-08
CA2929785A1 (en) 2015-06-18
BR112016013541B1 (pt) 2021-03-02
EP3080098A1 (en) 2016-10-19
JP2016540023A (ja) 2016-12-22
TW201536773A (zh) 2015-10-01
MX2016006351A (es) 2016-08-01
WO2015086636A1 (en) 2015-06-18
KR101822767B1 (ko) 2018-01-26
US20160304497A1 (en) 2016-10-20
CA2929785C (en) 2018-02-13
TWI540130B (zh) 2016-07-01
CN105722834B (zh) 2017-12-22
EP3080098B1 (en) 2017-12-06
US9802920B2 (en) 2017-10-31
CN105722834A (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
IL244492A0 (en) Broton tyrosine kinase inhibitors
HK1224173A1 (zh) 布魯頓氏酪氨酸激酶抑制劑和 抑制劑的組合
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1217198A1 (zh) 蛋白激酶抑制劑
EP2925740A4 (en) INHIBITORS OF BRUTON TYROSINE KINASE
HK1219421A1 (zh) 激酶抑制劑的組合及其用途
HK1220459A1 (zh) 激酶抑制劑
SG10202101389TA (en) Crystalline forms of a bruton’s tyrosine kinase inhibitor
EP3174539A4 (en) Inhibitors of bruton's tyrosine kinase
EP2858500A4 (en) INHIBITORS OF BRUTON TYROSINE KINASE
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
LT3386991T (lt) Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai
HK1218119A1 (zh) 蛋白激酶抑制劑
HK1210461A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1219104A1 (zh) 激酶抑制劑
EP2988744A4 (en) THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
HK1210779A1 (zh) 酪氨酸激酶抑制劑
HK1217695A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1218416A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
EP3030241A4 (en) INHIBITORS OF ACK1 / TNK2.TYROSINE KINASE
EP2968995A4 (en) INHIBITORS OF LRRK2 KINASE ACTIVITY
HK1226070B (zh) 酪氨酸蛋白激酶抑制劑
EP2988738A4 (en) THERAPEUTIC APPLICATIONS OF KINASEHEMMERN